Arcadia Biosciences, Inc.

Arcadia Biosciences reported a net loss of $6.3 million for the second quarter of 2026, widening from $4.5 million in the same period last year. For the first six months of 2026, the net loss significantly increased to $10.7 million from $1.9 million in the prior year. The company's management expressed substantial doubt about its ability to continue as a going concern, citing insufficient cash to meet anticipated requirements for the next 12 months. Despite a June 2026 private placement raising $4.0 million, the company recognized a $5.4 million valuation loss related to the offering, and also faced a default on a $2.0 million promissory note from Above Food Corp.

Arcadia Biosciences reported its second quarter and first half 2026 financial results, highlighting a net cash usage of only $319K in Q2 and a cash balance of $4.2 million at quarter-end. The company successfully closed a $4 million private placement in June. While total revenues slightly decreased to $1.443 million in Q2 and $2.543 million in H1, net losses were $6.266 million and $10.651 million respectively, impacted by valuation losses and offering costs. The company emphasized a significant reduction in SG&A expenses and announced plans for new product launches in late 2026 and early 2027.

Arcadia Biosciences, Inc. will hold its 2026 Annual Meeting of Stockholders on September 10, 2026, to vote on several key proposals. The company is seeking approval for a reverse stock split, with a ratio between 1-for-2 and 1-for-10, to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a deficiency letter on August 4, 2026. Stockholders will also vote on the potential issuance of common stock from Series A-1 Preferred Investment Options, which could generate approximately $3.5 million, and the approval of a new 2026 Omnibus Equity Incentive Plan.

Arcadia Biosciences, Inc. received a notice from Nasdaq on August 4, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share for continued listing. The company's common stock traded below this threshold for 30 consecutive business days. Arcadia has an initial 180-calendar-day period, until February 1, 2027, to regain compliance, and plans to evaluate options, including a reverse stock split.

Arcadia Biosciences, Inc. updated its 2025 Summary Compensation Table to reflect a discretionary cash bonus payment of $169,000 to CEO Thomas J. Schaefer for the 2025 year, bringing his total compensation to $473,058. This update follows a previous filing where the bonus amount was not yet determinable. Additionally, the company announced that its 2026 annual meeting of stockholders will be held on September 10, 2026, a change of more than 30 calendar days from the anniversary of the 2025 meeting.

Arcadia Biosciences, Inc. announced the closing of a private placement of securities, raising approximately $4 million before expenses. The offering included pre-funded warrants and Series A-1 and Series A-2 preferred investment options to purchase common stock. The company intends to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.

Arcadia Biosciences, Inc. announced the closing of its previously announced private placement, generating approximately $4 million in gross proceeds. The offering included the sale of 3,883,496 shares of common stock (or pre-funded warrants) and associated Series A-1 and Series A-2 preferred investment options at a purchase price of $1.03 per share. The net proceeds from this financing will be allocated towards working capital and general corporate purposes.

Arcadia Biosciences, Inc. announced it has entered into securities purchase agreements for a private placement expected to generate approximately $4 million in gross proceeds. The offering includes 3,883,496 shares of its common stock (or pre-funded warrants) and associated Series A-1 and Series A-2 preferred investment options, priced at $1.03 per share. The net proceeds from this offering will be utilized for working capital and general corporate purposes.

Arcadia Biosciences reported a net loss of $4.4 million for the first quarter of 2026, a significant decline from a net income of $2.6 million in the prior year's quarter, with product revenues decreasing to $1.1 million. The company's financial statements indicate substantial doubt about its ability to continue as a going concern due to insufficient cash and ongoing operating losses. During the quarter, Arcadia completed a January 2026 Inducement Offer, generating $2.1 million in proceeds but incurring a $2.9 million loss related to the offer.

Arcadia Biosciences reported a net loss of $4.4 million for the first quarter of 2026, a significant decrease from a net income of $2.6 million in Q1 2025. Total revenues declined 8% to $1.1 million, primarily due to a revenue reserve release in the prior year, despite an 18% increase in Zola coconut water volumes. The company achieved its lowest SG&A expenses in its history, generated $2.1 million from preferred investment option exercises, and plans a new product launch this fall.